Biotech bounces back on optimism and deals


Biotech stocks, among the biggest losers in the sell-off, are soaring.

The speculative sector is benefiting from renewed optimism among investors. Fundamental drivers such as deal making, new drug approvals and big investor buying provide reassurance that the rally may persist.


Back to top button